From page 1 of the announcementThe meeting was attended by more...

From page 1 of the announcement

The meeting was attended by more than 40 participants and feedback from the meeting has been very positive regarding the data from the completed Phase 1b atopic dermatitis patient study, the study design and the assessment of the novel Permetrex™ BTX 1204 formulation which has been shown to avoid the burning and stinging associated with recently approved topical products.

From page 2 of the announcement

Before the recent approval of Eucrisa® (crisaborole), there had been no new topically applied drugs approved for atopic dermatitis for more than 15 years, and based on successful Phase 3 studies, Pfizer acquired the company that developed Eucrisa® (Anacor Pharmaceuticals Inc.) for US$5.2 billion in May 2016. Studies show that Eucrisa® has little to no impact on itch, which remains a key unmet need for atopic dermatitis patients. The BTX 1204 Phase 1b patient study results suggests that BTX 1204 potentially has a broader mechanism of action than Eucrisa®, with substantial reduction in the key signs of atopic dermatitis already observed

Cheers